Drug Profile
Sotigalimab - Pyxis Oncology
Alternative Names: APX 005; APX 005M; EPI-0050; PYX-107Latest Information Update: 05 Jan 2024
Price :
$50
*
At a glance
- Originator Epitomics
- Developer Arcus Biosciences; Bristol-Myers Squibb; Parker Institute for Cancer Immunotherapy; Pyxis Oncology; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center; Yale University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; CD40 antigen stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Gastric cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Rectal cancer; Soft tissue sarcoma
- Phase I/II Non-small cell lung cancer
- No development reported Brain cancer; Glioma; Renal cell carcinoma; Solid tumours
Most Recent Events
- 22 Dec 2023 Apexigen terminates a phase II trial in Malignant melanoma (Metastatic disease, Inoperable/Unresectable) in Poland and Spain (IV) based on a business decision (NCT04337931)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease) in USA (IV, Infusion)
- 28 Oct 2023 No recent reports of development identified for phase-I development in Rectal cancer(Combination therapy, First-line therapy) in USA (IV, Infusion)